A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/00 (2006.01) A61K 9/19 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2654510
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
La présente invention concerne des formulations ophtalmiques d'une protéine de fusion antagoniste spécifique du facteur de croissance endothélial vasculaire (VEGF), appropriées à une administration intravitréenne dans l'AEil. Les formulations ophtalmiques contiennent une formulation liquide stable et une formulation lyophilisable. De préférence, la protéine antagoniste comporte la séquence d'acides aminés présentée dans la séquence SEQ ID NO : 4.
Dix Daniel
Frye Kelly
Furfine Eric
Graham Kenneth S.
Blake Cassels & Graydon Llp
Regeneron Pharmaceuticals Inc.
LandOfFree
Vegf antagonist formulations suitable for intravitreal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vegf antagonist formulations suitable for intravitreal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vegf antagonist formulations suitable for intravitreal... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1368301